BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1237 related articles for article (PubMed ID: 26957312)

  • 21. Digitoxin synergizes with sorafenib to inhibit hepatocelluar carcinoma cell growth without inhibiting cell migration.
    Xiao Y; Yan W; Guo L; Meng C; Li B; Neves H; Chen PC; Li L; Huang Y; Kwok HF; Lin Y
    Mol Med Rep; 2017 Feb; 15(2):941-947. PubMed ID: 28035421
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy.
    Chao TI; Tai WT; Hung MH; Tsai MH; Chen MH; Chang MJ; Shiau CW; Chen KF
    Cancer Lett; 2016 Feb; 371(2):205-13. PubMed ID: 26679051
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
    Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
    Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
    [TBL] [Abstract][Full Text] [Related]  

  • 24. By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma.
    Li S; Dai W; Mo W; Li J; Feng J; Wu L; Liu T; Yu Q; Xu S; Wang W; Lu X; Zhang Q; Chen K; Xia Y; Lu J; Zhou Y; Fan X; Xu L; Guo C
    Int J Cancer; 2017 Dec; 141(12):2571-2584. PubMed ID: 28857200
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sorafenib and triptolide as combination therapy for hepatocellular carcinoma.
    Alsaied OA; Sangwan V; Banerjee S; Krosch TC; Chugh R; Saluja A; Vickers SM; Jensen EH
    Surgery; 2014 Aug; 156(2):270-9. PubMed ID: 24953273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells.
    Louandre C; Marcq I; Bouhlal H; Lachaier E; Godin C; Saidak Z; François C; Chatelain D; Debuysscher V; Barbare JC; Chauffert B; Galmiche A
    Cancer Lett; 2015 Jan; 356(2 Pt B):971-7. PubMed ID: 25444922
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma.
    Ou DL; Shyue SK; Lin LI; Feng ZR; Liou JY; Fan HH; Lee BS; Hsu C; Cheng AL
    Oncotarget; 2015 Sep; 6(29):27953-65. PubMed ID: 26172295
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thirty-kilodalton Tat-interacting protein suppresses tumor metastasis by inhibition of osteopontin transcription in human hepatocellular carcinoma.
    Zhao J; Lu B; Xu H; Tong X; Wu G; Zhang X; Liang A; Cong W; Dai J; Wang H; Wu M; Guo Y
    Hepatology; 2008 Jul; 48(1):265-75. PubMed ID: 18537194
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sorafenib and TRAIL have synergistic effect on hepatocellular carcinoma.
    Nojiri K; Sugimoto K; Shiraki K; Tameda M; Inagaki Y; Ogura S; Kasai C; Kusagawa S; Yoneda M; Yamamoto N; Takei Y; Nobori T; Ito M
    Int J Oncol; 2013 Jan; 42(1):101-8. PubMed ID: 23123700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway.
    Lu M; Fei Z; Zhang G
    Biomed Pharmacother; 2018 Jan; 97():1282-1288. PubMed ID: 29156516
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
    Chen B; Wei W; Ma L; Yang B; Gill RM; Chua MS; Butte AJ; So S
    Gastroenterology; 2017 Jun; 152(8):2022-2036. PubMed ID: 28284560
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rhamnetin induces sensitization of hepatocellular carcinoma cells to a small molecular kinase inhibitor or chemotherapeutic agents.
    Jia H; Yang Q; Wang T; Cao Y; Jiang QY; Ma HD; Sun HW; Hou MX; Yang YP; Feng F
    Biochim Biophys Acta; 2016 Jul; 1860(7):1417-30. PubMed ID: 27091611
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
    Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meloxicam combined with sorafenib synergistically inhibits tumor growth of human hepatocellular carcinoma cells via ER stress-related apoptosis.
    Zhong J; Xiu P; Dong X; Wang F; Wei H; Wang X; Xu Z; Liu F; Li T; Wang Y; Li J
    Oncol Rep; 2015 Oct; 34(4):2142-50. PubMed ID: 26252057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activation of AMP-activated protein kinase by retinoic acid sensitizes hepatocellular carcinoma cells to apoptosis induced by sorafenib.
    Ishijima N; Kanki K; Shimizu H; Shiota G
    Cancer Sci; 2015 May; 106(5):567-75. PubMed ID: 25683251
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinoma.
    Liu LP; Ho RL; Chen GG; Lai PB
    Clin Cancer Res; 2012 Oct; 18(20):5662-71. PubMed ID: 22929805
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells.
    Chen G; Nicula D; Renko K; Derwahl M
    Oncol Rep; 2015 Apr; 33(4):1994-2000. PubMed ID: 25683253
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression.
    Hsu C; Lin LI; Cheng YC; Feng ZR; Shao YY; Cheng AL; Ou DL
    Clin Cancer Res; 2016 May; 22(10):2555-64. PubMed ID: 26603262
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.
    Wang Z; Zhou J; Fan J; Qiu SJ; Yu Y; Huang XW; Tang ZY
    Clin Cancer Res; 2008 Aug; 14(16):5124-30. PubMed ID: 18698030
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway.
    Tan W; Zhu S; Cao J; Zhang L; Li W; Liu K; Zhong J; Shang C; Chen Y
    Oncol Res; 2017 Nov; 25(9):1543-1553. PubMed ID: 28276313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 62.